<p>Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalised patients with Covid-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.</p>.<p>The drugmaker said on Monday it analyzed data from 98,654 patients from three retrospective studies of the real-world treatment of hospitalised Covid-19 patients.</p>.<p>Remdesivir achieved statistically significant 54% and 23% reduction in risk of mortality among the analysed patients in two of the studies, the company said. The data was presented at the World Microbe Forum (WMF) this week.</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/national/is-second-covid-wave-over-positivity-rate-below-5-for-14-days-but-experts-say-end-still-far-999868.html" target="_blank">Is second Covid wave over? Positivity rate below 5% for 14 days but experts say end still far</a></strong></p>.<p>Gilead said the results were consistently observed at different timeframes over the course of the pandemic and across geographies.</p>.<p>Remdesivir has been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan.</p>
<p>Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalised patients with Covid-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.</p>.<p>The drugmaker said on Monday it analyzed data from 98,654 patients from three retrospective studies of the real-world treatment of hospitalised Covid-19 patients.</p>.<p>Remdesivir achieved statistically significant 54% and 23% reduction in risk of mortality among the analysed patients in two of the studies, the company said. The data was presented at the World Microbe Forum (WMF) this week.</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/national/is-second-covid-wave-over-positivity-rate-below-5-for-14-days-but-experts-say-end-still-far-999868.html" target="_blank">Is second Covid wave over? Positivity rate below 5% for 14 days but experts say end still far</a></strong></p>.<p>Gilead said the results were consistently observed at different timeframes over the course of the pandemic and across geographies.</p>.<p>Remdesivir has been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan.</p>